What are the take‑home medications for a patient with rheumatic heart disease?

Take-Home Medications for Rheumatic Heart Disease

All patients with rheumatic heart disease must receive lifelong benzathine penicillin G 1.2 million units intramuscularly every 4 weeks as the cornerstone of secondary prophylaxis, with additional medications added based on specific complications such as heart failure, atrial fibrillation, or severe valve disease. 1, 2

Core Antibiotic Prophylaxis (Required for All Patients)

First-Line Regimen

• Benzathine penicillin G 1.2 million units intramuscularly every 4 weeks is the gold standard, carrying Class I, Level A evidence and providing approximately 10-fold greater protection than oral regimens (0.1% vs 1% recurrence rate). 2, 3, 4

• For high-risk patients—those with prior recurrence despite adherence, ongoing high streptococcal exposure (teachers, daycare workers, healthcare workers in endemic areas, parents of young children), or living in high-incidence regions—shorten the interval to every 3 weeks to maintain protective penicillin levels. 1, 2, 3

Alternative Regimens (Penicillin Allergy Only)

• Penicillin V 250 mg orally twice daily is the preferred second-line option for penicillin-allergic patients. 1, 3

• Sulfadiazine 1 g orally once daily (0.5 g for patients ≤27 kg) is an alternative for penicillin-allergic patients. 1, 3

• Macrolide or azalide antibiotics (erythromycin, clarithromycin, or azithromycin) are reserved only for patients allergic to both penicillin and sulfadiazine. 1, 5

Critical Caveat on Macrolides

• Never prescribe macrolides to patients taking CYP3A inhibitors including azole antifungals (fluconazole, itraconazole), HIV protease inhibitors, or certain SSRIs due to risk of QT prolongation and drug interactions. 1, 2, 4

Duration of Prophylaxis

Clinical Scenario	Duration (whichever is longer)
Rheumatic fever with carditis AND residual valve disease	10 years after last attack OR until age 40
Rheumatic fever with carditis WITHOUT residual valve disease	10 years after last attack OR until age 21
Rheumatic fever WITHOUT carditis	5 years after last attack OR until age 21
High-risk occupational/community exposure	Lifelong prophylaxis

1, 2

Non-Negotiable Rule

• Secondary prophylaxis must continue even after valve replacement or repair because surgery does not eliminate the risk of recurrent acute rheumatic fever. 2, 3

Heart Failure Medications (When LV Dysfunction Develops)

When left ventricular systolic dysfunction or symptomatic heart failure develops, initiate guideline-directed medical therapy immediately. 1, 2

Standard Heart Failure Regimen

• Diuretics (furosemide or bumetanide) for volume overload and symptomatic relief. 1, 2

• ACE inhibitors or ARBs (lisinopril, enalapril, losartan, valsartan) for afterload reduction and ventricular remodeling. 1, 2

• Beta-blockers (metoprolol succinate, carvedilol, bisoprolol) for heart rate control and mortality benefit, particularly critical in mitral stenosis where diastolic filling time is paramount. 1, 2

• Aldosterone antagonists (spironolactone or eplerenone) for additional mortality benefit in advanced heart failure. 1

• Sacubitril/valsartan may replace ACE inhibitor/ARB in appropriate candidates with reduced ejection fraction. 1

Critical Warning for Stenotic Lesions

• In patients with mitral stenosis or aortic stenosis, avoid abrupt blood pressure lowering as it can precipitate hemodynamic collapse; titrate vasodilators cautiously. 1, 2

Anticoagulation (For Atrial Fibrillation or High Thromboembolic Risk)

• Anticoagulation is indicated for all patients with rheumatic heart disease who develop atrial fibrillation. 2

• Consider anticoagulation even in sinus rhythm if the patient has very severe left atrial dilatation, spontaneous echo contrast on echocardiography, or concurrent heart failure. 2

• Warfarin remains the preferred anticoagulant in rheumatic mitral stenosis with atrial fibrillation (target INR 2.0-3.0), though direct oral anticoagulants may be considered after individualized risk-benefit discussion. 2

Rate Control for Atrial Fibrillation

• Beta-blockers are first-line for rate control in atrial fibrillation, especially important in mitral stenosis. 2

• Digoxin may be added for additional rate control when beta-blockers alone are insufficient. 2

Infective Endocarditis Prophylaxis (Selective Use Only)

Routine IE prophylaxis is NOT recommended for rheumatic heart disease alone. 2, 3, 4

Antibiotic Prophylaxis Before Dental Procedures IS Indicated Only For:

• Patients with prosthetic cardiac valves (including transcatheter-implanted prostheses). 2
• Patients with prosthetic material used for valve repair (annuloplasty rings, neochords, clips). 2
• Patients with prior infective endocarditis. 2

Dental Procedures Requiring Prophylaxis

• Only procedures that manipulate gingival tissue, the periapical region of teeth, or perforate oral mucosa. 1, 2

Important Exception

• For patients already on benzathine penicillin G prophylaxis who require IE prophylaxis for dental procedures, use a non-penicillin agent (such as clindamycin or a macrolide) because oral α-hemolytic streptococci may have developed penicillin resistance. 4, 6

Most Important Preventive Measure

• Maintaining optimal oral hygiene through regular professional dental care is more important than antibiotic prophylaxis for preventing infective endocarditis. 1, 2, 3

Vaccinations (All Patients)

• Influenza vaccination annually according to standard adult schedules. 1, 2

• Pneumococcal vaccination (both PCV and PPSV series) according to standard adult schedules. 1, 2

Common Pitfalls to Avoid

• Never discontinue secondary prophylaxis prematurely, even if the patient feels well, has a normal echocardiogram, or has undergone valve surgery—the risk of recurrent rheumatic fever persists. 2, 3, 4

• Never switch from intramuscular to oral prophylaxis based on drug availability—oral regimens have 10-fold higher failure rates even with perfect adherence; use oral only as a temporary bridge during benzathine penicillin G shortages, then resume injections immediately when supply is restored. 4, 7

• Never stop prophylaxis at arbitrary age cutoffs without evaluating individual risk factors including ongoing streptococcal exposure, severity of valvular disease, and time since last rheumatic attack. 2, 3

• Do not prescribe oral prophylaxis as equivalent to intramuscular—the majority of prophylaxis failures occur with oral regimens due to adherence issues; consider permanent switch to oral only in late adolescence/young adulthood after ≥5 years free of attacks (Class IIb recommendation). 4, 7

Special Consideration: Severe Valve Disease

Recent evidence suggests that patients with severe mitral stenosis, aortic stenosis, aortic insufficiency, or reduced left ventricular systolic function may be at elevated risk of cardiovascular compromise following benzathine penicillin G injections. 7

• For these high-risk patients, strongly consider switching to oral prophylaxis (penicillin V 250 mg twice daily or sulfadiazine 1 g daily) as the risk of adverse reaction to BPG may outweigh its benefit. 7

• Implement vasovagal risk-reduction strategies for all patients receiving BPG, including adequate hydration, supine positioning during and after injection, and extended observation periods. 7